E303
Payments companies reported to CMS as associated with E303. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with E303, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with E303
These are the largest totals companies reported as associated with E303. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Terence Friedlander | San Francisco, CA | Hematology & Oncology | $8,385.35 |
| Vandana Abramson | Nashville, TN | Medical Oncology | $7,345.35 |
| Edward Garon | Los Angeles, CA | Hematology & Oncology | $6,305.35 |
| Pasi Antero Janne | Boston, MA | Medical Oncology | $5,265.35 |
| Jonathan Rosenberg | New York, NY | Medical Oncology | $1,110.00 |
| Joyce O'Shaughnessy | Dallas, TX | Medical Oncology | $1,061.00 |
| Evan Yu | Seattle, WA | Medical Oncology | $1,040.00 |
| Matthew Galsky | New York, NY | Medical Oncology | $570.00 |
| Sara Tolaney | Boston, MA | Hematology & Oncology | $520.00 |
Prescribed E303?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.